Armand Bensussan

This inventor holds 20 USPTO granted patents and 29 published patent applications, plus 4 CIPO patents and 11 EPO patents. Top assignees: National Institute of Health and Medical Research, Mablife, Orega Biotech. Active years: 2008-2025.

USPTO Granted Patents = 20 (Patent Applications = 29)

% Patents Active = 50.0

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 11 (Patent Applications = 32)

Average Co-Inventor Count = 3.8

ph-index = 8

Forward Citations = 124(Granted Patents)

Location History:

Paris, FR (2008 - 2022)
Creteil, FR (2010 - 2023)

Company Filing History:

18 out of 1,853

National Institute of Health and Medical Research

Centre National De La Recherche Scientifique

patents

6. 2 out of 2

Medecine Et Innovation

patents

7. 1 out of 1,265

Dana-Farber-Cancer Institute Inc.

patents

8. 1 out of 1

Institut Jean Godinot

patent

9. 1 out of 1

Institut Régional Du Cancer De Montipellier

patent

10. 1 out of 1

Monoclonal Antibodies Therapeutics

patent

11. 1 out of 297

Universitè De Montpellier

patents

12. 1 out of 111

Université Paris Diderot-Paris 7

patents

where one patent can have more than one assignee

Years Active: 2008-2025

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12319745 - Antibodies having specificity for CD38 and uses thereof (2025-06-03),

2. 11685792 - Antibodies against human CD39 and use thereof for inhibiting T regulatory cells activity (2023-06-27),

3. 11365392 - Ex vivo generation of MHCII restricted CD4FOXP3regulatory T cells and therapeutic uses thereof (2022-06-21),

4. 11198851 - Ex vivo generation of γδ Foxp3regulatory T cells and therapeutic uses thereof (2021-12-14),

5. 11186635 - Monoclonal antibodies binding to the CD160 transmembrane isoform (2021-11-30),

6. 10662253 - Antibodies against human CD39 and use thereof for inhibiting T regulatory cells activity (2020-05-26),

7. 10351623 - Antagonists of IL-17 isoforms and their uses (2019-07-16),

8. 10208124 - Anti-CD160 specific antibodies for the treatment of eye disorders based on neoangiogenesis (2019-02-19),

9. 9834601 - Antagonists of IL-17 isoforms and their uses (2017-12-05),

10. 9676847 - IL-17 antagonist antibodies (2017-06-13),

11. 9045544 - Anti-CD160 specific antibodies for the treatment of eye disorders based on neoangiogenesis (2015-06-02),

12. 8518655 - Means for the diagnosis and therapy of CTCL (2013-08-27),

13. 8444978 - Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2 (2013-05-21),

14. 8409573 - Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells (2013-04-02),

15. 8268308 - Means for the diagnosis and therapy of CTCL (2012-09-18),

Title: The Innovative Mind of Armand Bensussan

Introduction: Armand Bensussan, a visionary inventor hailing from Paris, FR, has made significant contributions to the world of technology and innovation through his groundbreaking creations.

Latest Patents: Armand Bensussan's latest patents focus on renewable energy solutions, with a series of inventions aimed at harnessing solar power more efficiently and sustainably.

Career Highlights: With a career spanning over two decades, Armand Bensussan has established himself as a leading figure in the field of clean energy technology. His innovative designs have revolutionized the way we approach environmental sustainability.

Collaborations: Throughout his career, Armand Bensussan has collaborated with top research institutions and universities to further his inventions. His partnerships have led to the development of cutting-edge technologies that are shaping the future of renewable energy.

Conclusion: Armand Bensussan's passion for innovation and commitment to creating a more sustainable world have solidified his reputation as a pioneering inventor in the realm of clean energy technology. His contributions continue to inspire and drive progress in the industry.